Sunday, June 11, 2017
8:15 am – 9:15 am
Addressing America’s Opioid Crisis:
How Practitioners Can be Agents for Change
Principal Deputy Administrator
Office of the Administrator
Substance Abuse and Mental Health Services Administration
Ms. Enomoto has been delegated the functions, duties, and authorities of the Administrator of The Substance Abuse and Mental Health Services Administration (SAMHSA) .
Ms. Enomoto oversees an agency with four centers and four offices, over 600 employees, and a budget of $3.7 billion. Through data, policy, public education, and grants, Ms. Enomoto and the SAMHSA team advance the agency’s mission to reduce the impact of substance abuse and mental illness on America’s communities.
Ms. Enomoto has served as Principal Deputy Administrator and principal advisor to the SAMHSA Administrator on operations, policies, and programmatic activities for the agency since August 2011. Prior to that, Ms. Enomoto served as the Director of the Office of Policy, Planning, and Innovation, where she developed, coordinated, and communicated SAMHSA policies across the full spectrum of mental health and substance abuse issues. From 2005-2009, Ms. Enomoto served as the Principal Senior Advisor to three SAMHSA Administrators, and as the Acting Deputy Administrator between 2008 and 2009. She began her tenure at SAMHSA in 1998 as a Presidential Management Fellow. She began her career in research and clinical services with a focus on minority mental health and trauma.
Ms. Enomoto has received awards in recognition of her work, including the Arthur S. Flemming Award, the American College of Mental Health Administration King Davis Award, and the Secretary’s Award for Distinguished Service.
Ms. Enomoto earned her bachelor’s degree in psychology and master’s degree in clinical psychology from the University of California, Los Angeles and is a graduate of Harvard University’s Kennedy School of Government, Senior Managers in Government Program.
Monday, June 12, 2017
8:00 am - 9:00 am
The Role of ADFs in Curbing Opioid Abuse:
Can ADFs Reduce Opioid Abuse?
|Lynn R. Webster, MD, FACPM, FASAM.
Vice President of Scientific Affairs
PRA Health Sciences
American Academy of Pain Medicine (AAPM)
| Dr. Lynn Webster has dedicated more than three decades to becoming an expert in the field of pain management. He is the vice president of Scientific Affairs of PRA Health Sciences and past president of the American Academy of Pain Medicine.
A leading voice in trying to help physicians safely treat pain patients, Dr. Webster actively works within the industry to develop safer and more effective therapies for chronic pain and addiction. He is board certified in anesthesiology and pain medicine, and is also certified in addiction medicine.
Dr. Webster lectures extensively on the subject of preventing opioid abuse and criminal diversion in chronic pain patients and has authored more than 300 scientific abstracts, manuscripts, journal articles and a book entitled Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners, many of which are the basis for training physicians who are studying pain.
Dr. Webster has played an instrumental role in his industry as a strong advocate for safe and effective
pain resolution methods. The Opioid Risk Tool (ORT), which he developed, is currently used and is the standard in multiple countries and thousands of clinics worldwide. He spends most of his time now developing safer and more effective therapies for chronic pain and campaigning for safer use of medications. He received his doctorate of medicine from the University of Nebraska and later completed his residency at the University of Utah Medical Center’s Department of Anesthesiology.
Dr. Webster has been quoted by multiple media sources, including in the Los Angeles Times and The Wall Street Journal, and has given over 250 presentations across the United States and internationally. He is the author of The Painful Truth: What Chronic Pain Is Really Like and Why It Matters to Each of Us (Webster Media LLC).
Tuesday, June 13, 2017
8:00 am - 9:00 am
Tackling the Opioid Epidemic with Science:
Studies from the Laboratory and Clinic
Sharon Walsh, PhD
Sharon Walsh, PhD, is a Professor in the Departments of Behavioral Science and Psychiatry, and Director of the Center on Drug and Alcohol Research in the College of Medicine at the University of Kentucky.
Dr. Walsh earned her MS and PhD from Rutgers University in Behavioral Neuroscience and completed her postdoctoral studies at Johns Hopkins University School of Medicine. She remained at Johns Hopkins for 13 years as a faculty member of the Behavioral Pharmacology Research Unit before leaving at the rank of Professor for the University of Kentucky in 2005.
Dr. Walsh’s clinical research is focused on pharmacological issues in opioid and cocaine dependence and has been supported by the National Institute on Drug Abuse, private foundations and the pharmaceutical industry. She has conducted studies on the pharmacodynamic and pharmacokinetic characteristics of opioid treatment agents, including buprenorphine, methadone, LAAM and lofexidine, has conducted abuse liability evaluations of opioid analgesics, and has evaluated potential pharmacotherapies for efficacy and safety in the treatment of cocaine dependence.
Dr. Walsh was the recipient of the Presidential Early Career award for Scientists and Engineers (1997), the Joseph Cochin Young Investigator Award (2000) and the Betty Ford Award (2010). She has served on numerous review and advisory boards, including grant review panels for NIDA and the VA, advisory panels for the Food and Drug Administration, the National Institutes of Health and American Society for Addiction Medicine. She has served as President of the College on Problems of Drug Dependence and has published more than 90 manuscripts and book chapters on substance abuse.
| ICOO 2017 Conference Times
|Saturday June 10, 2017|
|Exhibitor Setup 2:30 pm to 5:00 pm|
|Attendee Registration 2:30 pm to 5:00 pm|
|Sunday June 11, 2017|
|Attendee and Exhibitor Registration 7:00 am to 6:00 pm
Conference day begins at 8:00 am - day ends at 8:00 pm
|Monday, June 12, 2017|
|Attendee and Exhibitor Registration 7:00 am to 5:00 pm
Conference day begins at 8:00 am - day ends at 5:15 pm
|Tuesday, June 13, 2017|
| Attendee and Exhibitor Registration 7:00am to 1:30pm
| Conference day begins at 8:00 am -
Conference closes at 1:15 pm
|Exhibit Breakdown 1:30pm to 4:00pm|